
Janux Narrows Losses as JANX011 Data Nears
The San Diego drug developer cut its quarterly net loss to $21.6 million ahead of early Phase 1 results due November 9, 2026.
Biotech in San Diego runs on research institutes, drug developers and the startups that spin out of them, and coverage here follows all of it. Reporting takes in clinical trial results, gene editing, genomics, financings and acquisitions across the city's life sciences sector.

The San Diego drug developer cut its quarterly net loss to $21.6 million ahead of early Phase 1 results due November 9, 2026.
November 3, 2026
BlossomHill Courts Investors With Lung Cancer DrugThe San Diego biotech's investigational EGFR inhibitor is still in clinical development, with no efficacy results disclosed in this announcement.
October 26, 2026
Rakuten Medical Starts U.S. Phase 3 Cancer Drug TrialsThe San Diego firm moves to scale its light-activated treatment for solid tumors ahead of a planned 2028 FDA submission.
October 14, 2026
Adagene CEO to Present Clinical Update on October 15The leadership at the San Diego-based biotech will discuss its clinical development programs during a virtual industry conference.
October 12, 2026
Haynes Boone Opened New San Diego OfficeThe firm expanded its California presence to provide localized intellectual property and litigation support for biotech clients.
October 12, 2026
Oncolytics Biotech Secured New Immunotherapy PatentsThe San Diego firm extended its intellectual property portfolio to secure drug protection into the late 2040s.
October 12, 2026
Fate Therapeutics Appointed New Commercial LeadThe San Diego-based firm added a veteran executive to scale its clinical programs in autoimmunity and oncology.
October 9, 2026
San Diego Biotech Iambic Therapeutics Filed for IPOThe drug discovery startup aims to raise capital to fund its clinical pipeline and AI platform through 2028.
October 7, 2026
Byondis Will Present ADC Technology at World ADCThe company will detail its steric masking platform and preclinical oncology findings in San Diego this October.
October 5, 2026
Iambic Therapeutics Filed IND for Novel Cancer DrugThe San Diego biotech aims to initiate human trials for its AI-designed brain-penetrant KIF18A inhibitor.
September 22, 2026
San Diego AI Drug Firm Iambic Filed for IPOThe company plans to fund clinical trials for its pipeline using proceeds from its public market entry.
Regular subjects here include gene therapy and CRISPR programs moving through trials, biotech funding rounds and public offerings, partnerships between local drug developers and larger pharmaceutical companies, and genomics research with commercial applications. Coverage runs across the city and into the communities around it wherever a life sciences story crosses the line. Lab leases and facility buildouts surface as often as the science does, since the region's growth depends on available space. Fundraising conditions and the pace of clinical development are the two forces that most often shape how a San Diego biotech story unfolds.